

United Scientific Group Presents Virtual Series of Cancer R&D & ICHEM-2020

Immunotherapy in Cancer

Session Speakers

Joost J. Oppenheim, NIH/NCI, MD, USA

Title: Identification of Effective Combinations of Immunostimulants to Cure Mouse Tumors

Guido Kroemer, Gustave Roussy Comprehensive Cancer Center, INSERM, France

Title: Overcoming a Frequent Inborn Immune Defect in Breast Cancer Therapy

Lauren V. Wood, Chief Medical Officer, PDS Biotechnology, NJ

Title: Versamune (R-D0TAP): a Transformative Cationic Lipid Nanoparticle Technology Associated with Type I Interferon Specific Activation and Generation of Antibody, CD8 and CD4 T Cell Responses to Recombinant Proteins and Peptide Tumor Antigens

Wayne Godfrey, Vice President of Clinical Development at IGM Bioscience

Title: A Novel Approach to Engineering Antibody Based Immunotherapy

Scott K. Durum, NCI/CCR, NIH, MD, USA

Title: Title to be updated

Eduardo Davila, University of Colorado CU Comprehensive Cancer Center, CO

Title: Novel Gene Platforms to Maintain the Persistence and Antitumor Activity of TIL-, CAR-, and DC-Based Therapies

William Hearl, Ph.D. CEO, Immunomic Therapeutics, MD *Title: To be Updated*

Brian Francica, Tempest Therapeutics, CA

Title: Dual Antagonism of Prostaglandin Receptors EP2 and EP4 by TPST-1495 Suppresses Tumor Growth and Stimulates Antitumor Immunity

Jing H. Wang, University of Colorado Anschutz Medical Campus, CO

Title: MHC Class-I Independent Activation of Virtual-Memory CD8 T Cells Induced by Chemotherapeutic Agent-Treated Cancer Cells

Pooja Jain, Drexel University College of Medicine, Philadelphia, PA

Title: The MAPK/ERK-regulated MEF-2 isoforms as potential new target(s) for HTLV-1 induced Adult T-cell leukemia/lymphoma (ATLL)

Jason D. Marshall, Leidos Biomedical Research, Inc., NCI Campus at Frederick, MD

Title: Performance Optimization of a Novel HPV VLP Vaccine in Mice with Novel Adjuvants

Joseph Markowitz, Moffit Cancer Center, FL Title: Duality of NO in Melanoma

Yan Leyfman, Penn State College of Medicine, PA

Title: Finetune Your CARs: Building the Next Generation of Anti-Cancer Therapies

Jean Gariepy, Sunnybrook Research Institute, Toronto, Canada

Title: The COMP Platform: Development of High-Valency Protein-Based Agonists As Immunomodulators

Tel: +1 469-854-2280/81 Email: cancer.therapy@uniscigroup.org; contact@ichemmeetings.com Twitter: @KK_usgcancer